Boston QSP February 2019 Event Announcement
Boston- Please join us on Tuesday, February 19th, 2019 for the Boston QSP February Event. In collaboration with Boston University BEST Program, we present "Interdisciplinary Quantitative Systems Pharmacology Research: Present and Future" event series. The event series offers talks and panel discussions led by leaders in QSP research, to bring together students, postdocs, and professionals in industry and academia.
5:30-6:00 PM: Registration
6:00-6:15 PM: Talk by Dr. Cynthia (CJ.) Musante
Talk title: The Role of Quantitative Systems Pharmacology in Drug Discovery & Development: Present and Future
6:15-7:00 PM: Panel Discussion of Careers in Interdisciplinary Quantitative Systems Pharmacology Research
7:00-8:00 PM: Networking & Reception
Venue: Boston University 610 Commonwealth Avenue (Kilachand 101)
Sponsors: Boston University BEST Program, Boston University Biological Design Center, Boston University Industry Engagement
RSVP here. Limited seats.
* Please do not hesitate to RSVP on the waiting list if the RSVP is full as some guests "un-RSVP" as the event gets closer.
Dr. Cynthia J. (C.J.) Musante is a Senior Scientific Director and Head of the newly formed Quantitative Systems Pharmacology (QSP) Group in Early Clinical Development at Pfizer. She holds a doctoral degree in Applied Mathematics from North Carolina State University and has over eighteen years of experience in providing QSP modeling support to drug discovery & development programs. C.J. serves on the Executive Board of ISoP, was the Meeting Chair for ACoP 2018, and was the inaugural Chair of ISoP’s QSP Special Interest Group. She is a member of ASCPT’s Scientific Programming Committee and is Co-Chair of the QSP pre-conference to be held at ASCPT’s Annual Meeting in March 2019. In addition, she serves on the Editorial Board for CPT:PSP and is Co-Chair of the IQ Consortium Clinical Pharmacology Leadership Group’s QSP Working Group.
Gianluca Nucci, Ph.D is the Head of Early Clinical Development Clinical Pharmacology at Pfizer. His group provides clinical pharmacology leadership to integrate PK, PD, patient characteristics pharmacology and mechanistic disease understanding to inform translational and clinical development strategies, driving robust and successful PoM ESoE & PoC delivery via quantitative methodologies, innovative study/program design and model informed drug discovery and development to facilitate knowledge based decisions. Gianluca has > 15 years of experience in quantitative Clinical Pharmacology across multiple therapeutic areas and two major Pharma companies (GSK and Pfizer). Gianluca is on the Boston QSP Scientific Board.
Dr. Birgit Schoeberl currently is the Global Head of Modeling and Simulation, PK Sciences at Novartis. Before joining Novartis, Birgit served as interim Senior Vice President, Scientific Value, at GNS Healthcare. During her time at GNS, she focused on applying causal machine learning to drug development. Prior to GNS, she was a member of the founding team at Merrimack Pharmaceuticals where she spent over 12 years in different roles. In her latest role as Head of Discovery and Early Development, she gained broad experience in oncology drug discovery and development. Birgit and her leadership team were responsible for multiple preclinical and early clinical programs. Birgit received her Chemical Engineering degree from the Technical University in Karlsruhe, Germany, and her Ph.D. in Biological Engineering from the Max Planck Institute for Dynamics of Complex Technical Systems in Magdeburg. She was a post-doctoral fellow in the laboratories of Douglas Lauffenburger and Peter Sorger in the Biological Engineering Department at MIT. Birgit is on the Boston QSP Scientific Board.
Dean Bottino received his PhD in Applied Mathematics from Tulane University in 1996. His academic work at Tulane, and subsequently at University of Utah and UC Berkeley, consisted of spatiotemporal simulations of eukaryotic cell motility and chemotaxis. Dr. Bottino then moved into industry, joining Physiome Sciences in 2001, co-founding the BioAnalytics Group LLC in 2003, then moving on to Novartis in 2005, Roche in 2011 and Millennium (Takeda) in 2013. He has specialized in preclinical and clinical modeling and simulation in oncology since 2005.
Bill McCarty is a modeler and project team representative in the Pharmacokinetics and Drug Metabolism group at Amgen, Inc. in Cambridge, MA. He currently enjoys splitting his time between 1) providing preclinical modeling support (PK, PKPD, PBPK, QSP, etc.) to small and large molecule projects across therapeutic areas and 2) driving progression of drug discovery teams from discovery through lead selection as a project team representative. Before joining Amgen, Bill was a Ruth L. Kirschstein Postdoctoral Fellow at The Center for Engineering in Medicine, Massachusetts General Hospital, Harvard Medical School, and Shriners Hospitals for Children, Boston. He received his PhD from the University of California, San Diego in Bioengineering.
About Boston QSP
Boston QSP is a 501(c)(3) non-profit organization whose mission is to foster the sharing of QSP knowledge, challenges, solutions, and opportunities to advance the field as an interdisciplinary community in Boston.